1 Bringing innovation to global health Crucell 2010
2 Contents Our mission Crucell s mission is to protect human lives from infectious diseases by bringing meaningful innovation to global health. Research and development see page 12 Crucell is a global biopharmaceutical company focusing on the research and development, production and marketing of vaccines and antibodies against infectious disease worldwide. Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the paediatric, travel and endemic, and respiratory fields. In this report you can read all about our mission, vision, strategic pillars and our commitment to the principles of Corporate Social Responsibility. For inquiries, please contact Corporate Communications. Technologies see page 20 Overview Crucell at a glance 02 Crucell: A global perspective 06 Message from our CEO 08 Our business Research and development, technologies and products 10 Research and development 12 Technologies 20 Products 26 Products see page 26 Crucell s commitment to the world Taking responsibility 32 CSR highlights in Our CSR policy 36 Our CSR achievements, ambitions and targets 40
3 2010 key highlights 01 Revenues and other operating income 2010 Revenues and other operating income ( million) 105+ mln Product sales License revenues 32.7 Service fees 6.5 Other operating income, e.g. grants 35.6 Total Vaccine doses distributed in 2010 In more than 100 countries around the world mln Research and development investment in 2010 Compared to 70.2 mln in Product sales ( million) mln 25% Product sales in % 7% 7% Paediatric Travel and endemic Respiratory Other mln Total revenues and other operating income in 2010 Compared to mln in 2009.
4 02 Overview Crucell at a glance
5 Overview Crucell at a glance 03 Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. We do this by discovering, developing, manufacturing and marketing products that combat major threats to the health of people worldwide. Our specialty is fighting infectious diseases a growing healthcare challenge.
6 04 Overview Crucell at a glance Our Company Innovation is the driving force behind our strong research and development (R&D) pipeline, with promising products in pre-clinical and clinical development. In 2010 alone, Crucell distributed more than 105 million 1 vaccine doses in more than 100 countries around the world, and invested million in R&D. Crucell is deeply committed to being a good corporate citizen: a company that creates significant value for society. Our mission is to make a truly meaningful contribution to global health by directing our proven talent for innovation towards the fight against infectious diseases. An entrepreneurial mind-set and social responsibility go hand-in-hand at Crucell. In 2010, 1,400 dedicated and skilled Crucell employees worldwide worked to bring significant benefit to the lives of people worldwide. We are fully committed to the principles of corporate social responsibility (CSR) and place great value on doing more to benefit society than we strictly must do. Our mission underlies everything we do, from our core business activities to the sharing of scientific knowledge and community outreach programs in countries where help is needed the most. The combination of our innovative technologies, our core values and creative minds drives Crucell s success, which we measure in human and business terms. Crucell is headquartered in Leiden, the Netherlands, with offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, UK, the USA and Vietnam. Our strategy Infectious diseases are a major cause of illness and death throughout the world. The number of infectious outbreaks is increasing for many reasons: higher population density raises exposure to infectious agents, an aging population is more susceptible to infection, and a rise in global travel boosts the potential for spreading diseases across borders. In addition, natural disasters can have a devastating impact on sanitation, hygiene, infrastructure and healthcare facilities. At Crucell, we are dedicated to saving lives and preventing illness around the world. We focus strongly on unmet medical needs in developing countries, where infectious diseases exert their greatest toll. At the same time, we work to protect travelers and vulnerable groups living in industrialized countries. We target major health threats that demand innovative solutions, striving to lead rather than follow. We focus on infectious diseases because these pose an increasingly serious threat to the health of people worldwide and we have the expertise to make a real difference in this disease area. The combination of our scientific know-how, innovative technologies and quality products positions Crucell to become a major player in the biopharmaceutical arena. Our strategy is based on three business drivers: 1. A strong R&D pipeline with promising products in a range of major disease areas. 2. Cutting-edge technologies that enable the discovery, development and production of biopharmaceutical products. These proprietary technologies drive in-house innovation and generate licensing revenue. 3. A broad range of marketed vaccine products that together combat 12 major infectious diseases. 1. Our strong research and development pipeline Innovation is the driving force behind our strong and broad R&D pipeline, with promising products in pre-clinical and clinical development. Product candidates include flu-mab, an antibody effective against a 1 Figure based on Crucell s top five vaccines in terms of sales volumes: Quinvaxem, Hepavax-Gene, Epaxal, Vivotif and Inflexal V.
7 Overview Crucell at a glance 05 broad range of influenza virus strains, tuberculosis and malaria vaccines, and a rabies monoclonal antibody combination all produced on our unique PER.C6 human cell-line technology. Read more on page Our cutting-edge technologies Crucell s proprietary technologies offer unique advantages for biopharmaceutical innovation. This competitive edge is exemplified by our PER.C6 technology, which is ideally suited to the manufacture of vaccines and therapeutic proteins, such as antibodies. Compared to traditional production platforms, PER.C6 human cell-line technology provides higher yields at lower cost, as well as safety advantages. Crucell licenses its PER.C6 technology and other technologies to the biopharmaceutical industry. Important partners and licensees include, among others, Johnson & Johnson, DSM Biologics, Merck & Co., Novartis, sanofi pasteur and Pfizer/Wyeth. Read more on page Our broad range of innovative products Vaccines play a vital role in protecting against diseases and have contributed significantly to the improvement of global health. Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the paediatric, travel and endemic, and respiratory fields. We are one of the major suppliers of vaccines to supranational organizations in the developing world, and the first manufacturer to launch a fully liquid pentavalent vaccine, called Quinvaxem. This innovative combination vaccine protects against five important childhood diseases. Over 200 million doses have been sold since its launch in 2006 in more than 50 GAVI (the Global Alliance for Vaccines and Immunisation) countries. With this innovation, Crucell has become a major partner in protecting children in developing countries. Other products in Crucell s core portfolio include Hepavax-Gene, a vaccine against hepatitis B; Epaxal, the only aluminum-free hepatitis A vaccine on the market; Vivotif and Dukoral, oral vaccines against typhoid and cholera, respectively; and Inflexal V, a virosomal adjuvanted vaccine against influenza. Read more on page 26. Partners and licensees In addition to our own R&D activities, we have strategic partnerships with several leading healthcare companies, such as Johnson & Johnson, DSM Biologics, Merck, Novartis and sanofi pasteur. Through these agreements, our technologies play a vital role in the development of a vast number of vaccines and antibody products.
8 06 Overview Crucell: A global perspective China Marketing and sales. 2. Italy Marketing and sales. 3. Korea Marketing and sales + Manufacturing. 4. Netherlands (Headquarters) Marketing and sales. 5. Spain Marketing and sales + Manufacturing. 6. Sweden Marketing and sales + Manufacturing. 7. Switzerland Marketing and sales + Manufacturing. 8. UK Marketing and sales. 9. USA Marketing and sales.
9 Overview Crucell: A global perspective 07 Research and development Vaccines in development: Flavimun yellow fever vaccine. Influenza Seasonal cell-based seasonal vaccine. Universal Influenza cell-based universal vaccine. Tuberculosis recombinant AdVac based vaccine. Malaria recombinant AdVac based vaccine. Ebola and Marburg recombinant AdVac based vaccine. Technologies PER.C6 human cell line for development and manufacturing. AdVac used with PER.C6 to develop recombinant vaccines. MAbstract to discover novel drug targets and identify human monoclonal antibodies. HIV recombinant AdVac -based vaccine. HPV recombinant AdVac -based vaccine. RSV recombinant AdVac -based vaccine. Human monoclonal antibodies in development: Rabies antibody combination. Influenza antibodies. Hepatitis C antibody combination. Details on page 12 STAR to enhance yields of recombinant human antibodies and proteins. Virosome a vehicle enabling the use of virus antigens in the making of vaccines. Details on page 20 Products Paediatric: Quinvaxem fully liquid vaccine to protect against five important childhood diseases. Hepavax-Gene recombinant hepatitis B vaccine. Epaxal Junior low dosage, aluminum-free hepatitis A vaccine. MoRu-Viraten vaccine for protection against measles and rubella. Travel and endemic: Epaxal aluminum-free hepatitis A vaccine. Vivotif oral typhoid vaccine. Dukoral only internationally licensed oral vaccine against cholera (and ETEC). Respiratory: Inflexal V virosomal adjuvanted influenza vaccine. Details on page 26
10 08 Overview Message from our CEO I am therefore delighted that talks held with Johnson & Johnson during 2010 have resulted in Crucell becoming the center of excellence for vaccines within the world s largest and possibly most respected healthcare company. As a member of the Johnson & Johnson Family of Companies, we can do so much more to make the world we live in a healthier place. The combination of our two companies will enable Crucell to further accelerate growth, and our shared expertise and talent will help to make an even bigger difference in the lives of people worldwide. We are delighted by the prospect of pursuing our mission with the support of Johnson & Johnson that shares our passion for healthcare innovation, our values and our commitment to care for people. Crucell s mission to bring meaningful innovation to global health reflects a deep commitment to improving the lives of people worldwide. This underpins everything we do as a global organization and as individuals united by a common purpose. Protecting and contributing to society in the fullest possible sense and to the best of our ability is our core business, our passion and the essence of our company. Our commitment to the principles of corporate social responsibility is a logical extension of our mission to bring innovation to global health, focusing especially on the prevention of infectious diseases. During 2010, we distributed over 105 million 1 doses of vaccines to people around the world, with the majority going to infants in developing countries. The range of vaccines we have on the market prevents twelve major infectious diseases: childhood infections, travel and endemic illnesses, and respiratory disease. We estimate that a Crucell vaccine was given to 190 individuals 2 every minute during 2010, a thought that makes us very proud. However, I believe that the best measure of our impact on global health is not the number of doses we supply, but the number of deaths and cases of disease we prevent each year. In 2010, Crucell s top-five vaccines prevented more than 3.6 million cases of infectious disease and 809,823 deaths. 1 Crucell s core business is the discovery, development and delivery of innovative solutions for major health threats. Our specialty is the creation of much-needed immunization products: vaccines that safely 1 Figure based on Crucell s top five vaccines in terms of sales volumes: Quinvaxem, Hepavax-Gene, Epaxal, Vivotif and Inflexal V. 2 Figures based on Crucell s top 5 vaccines Quinvaxem, Hepavax-Gene, Epaxal, Vivotif and Inflexal V. Total 101,666,000 doses minus 2% waste (2,033,320 doses) = 99,632,680 doses sold in 2010 / minutes in 2010 = doses administered per minute.
11 Overview Message from our CEO 09 and effectively mobilize the body s own immune defenses against infections, and antibodies that provide ready-made immune protection against invading microbes. After clean water, immunization is believed to be the most cost-effective health intervention and its key role in promoting the socioeconomic development of countries is becoming increasingly clear. The world population is predicted to reach 7 billion in 2011 and protecting these billions of individuals from infectious diseases is more important and challenging than ever. Trends such as climate change, globalization, urbanization, wider travel and population aging are presenting new opportunities for infectious pathogens to thrive and spread. Doing our utmost to tackle this problem is our primary responsibility and our privilege. It lies at the heart of Crucell. More importantly, I see that we are expanding the boundaries of that reality, day by day. Innovation is the foundation on which Crucell was built, and the fuel driving us forward. Crucell s core business is the discovery, development and delivery of innovative solutions for major health threats. Our achievements so far are thanks to the tireless efforts and dedication of our loyal employees, Crucell s most important asset. In 2010 hundreds of talented people were recruited in order to further boost our capacity to bring innovation to global health going forward. Improving healthcare access The cover photograph of this booklet shows an Expanded Program on Immunization (EPI) session set up by the nongovernmental organization Friendship in collaboration with local governmental agents in Bangladesh. The mothers holding young babies are waiting in line for their infants to receive Crucell s Quinvaxem vaccine. With support from Crucell, Friendship has set up the cold chain to enable children in these remote char areas to be immunized. This initiative is one of many described in our corporate social responsibility (CSR) report in this booklet. The EPI was established by the World Health Organization (WHO) in 1974 with the aim of ensuring that all children in all countries benefit from life-saving vaccines. The first diseases targeted by the EPI were diphtheria, pertussis (whooping cough), tetanus, measles, poliomyelitis and tuberculosis. In 1977, the WHO established global policies for immunization and set the goal of universal immunization for all children by 1990, as an essential element of the WHO strategy to achieve health for all. In 2009, an estimated 82% of children globally had received at least three doses of diphtheria tetanus pertussis vaccine (DTP3) by one year of age, which has traditionally been used as an indicator of EPI coverage. Additional vaccines have progressively been added to the original six recommended by the WHO in The EPI remains committed to the goal of universal access to all relevant vaccines for all at risk. Information on the EPI was sourced from the WHO website. Ronald H.P. Brus President and Chief Executive Officer Leiden, the Netherlands, April 18, 2011
12 10 Our business Research and development, technologies and products At Crucell we bring meaningful innovation to global health. We do this by discovering, developing, manufacturing and marketing products that combat major threats to the health of people worldwide. Our specialty is fighting infectious diseases a growing healthcare challenge. In the following pages we highlight Crucell s key innovations in the field of research and development, our cutting-edge technologies and robust product portfolio. Research and development mln Invested in research and development in mln Doses distributed in Technologies 100 countries Crucell vaccines were distributed in more than 100 countries in Products
13 Our business Research and development, technologies and products 11 Development stage Discovery/ Pre-clinical Phase I Phase II Phase III Marketed Description Marketed products: Quinvaxem Fully liquid vaccine for protection against five childhood diseases. Hepavax-Gene Recombinant hepatitis B vaccine. Epaxal Junior Low-dosage, aluminum-free hepatitis A vaccine (0.25ml). MoRu-Viraten Vaccine for protection against measles and rubella. Epaxal Aluminum-free hepatitis A vaccine. Vivotif Oral typhoid vaccine. Dukoral Only internationally licensed oral vaccine against cholera. Inflexal V Virosomal adjuvanted influenza vaccine. Vaccines in development: Flavimun Yellow fever vaccine. Tuberculosis Recombinant AdVac -based tuberculosis vaccine. 1 Malaria Recombinant AdVac -based malaria vaccine. 2 Ebola and Marburg Recombinant AdVac -based Ebola and Marburg vaccine. 2 HIV Recombinant AdVac -based HIV vaccine. 3 Cell-based Influenza Seasonal influenza vaccine produced on PER.C6. Universal influenza Universal influenza vaccine produced on PER.C6. HPV Recombinant AdVac -based HPV vaccine. 4 RSV Recombinant AdVac -based RSV vaccine. 5 Human monoclonal antibodies in development: Rabies antibody combination Mix of two monoclonal antibodies for post-exposure treatment of rabies. 6 Influenza antibodies Hepatitis C antibody combination 1 Partnered with Aeras. 2 Partnered with NIH/NIAID, GSK. 3 Partnered with Harvard. 4 Human papilloma virus (HPV), partnered with Johnson & Johnson. 5 Respiratory syncytial virus (RSV), partnered with Johnson & Johnson. 6 Partnered with sanofi pasteur. Antibodies neutralizing a wide range of influenza subtypes, including H5 and H1. Neutralizing monoclonal antibody combination across all genotypes tested.
14 12 Our business Research and development
15 Our business Research and development 13 Crucell s research efforts focus on developing vaccines and antibodies that address infectious disease and unmet medical needs. In this section you can read more about the discovery and development of next-generation medical products facilitated by our range of innovative technologies.
16 14 Our business Research and development Our strong research and development pipeline Innovation is the driving force behind Crucell s future growth supported by a strong R&D pipeline. Our scientists focus on the discovery and development of much-needed solutions for major threats to human health particularly vaccines and antibodies for the prevention and treatment of infectious diseases. This has resulted in a broad pipeline of investigational products with the potential to revolutionize the fight against diseases such as influenza, rabies, malaria and tuberculosis. Vaccine development: based on AdVac technology AdVac technology involves the use of novel adenoviral vectors, such as Ad35 and Ad26, in vaccines for diseases caused by viruses, bacteria or parasites. These vectors are harmless adenoviruses that have been disabled so that they cannot replicate. A vector functions as an efficient gene taxi, delivering into the human body a fragment of DNA that carries the code for a protein of a specific pathogen. Once inside the body, the vectors express (produce) these proteins and present them to the person s immune system, which mounts its protective response. Using this versatile vaccine vector platform in combination with our PER.C6 manufacturing technology, we are working with our partners to develop vaccines against major threats to human health, including tuberculosis, malaria, Ebola and Marburg, HIV, human papilloma virus (HPV) and respiratory syncytial virus (RSV). See page 17. Tuberculosis (Phase II) Crucell joined forces with the nongovernmental organization (NGO) Aeras Global TB Vaccine Foundation in 2004 to develop a safe, effective and affordable vaccine against tuberculosis (TB). The traditional TB vaccine developed more than 85 years ago, Bacille Calmette Guérin (BCG), does not reliably prevent pulmonary disease the most common form of TB so there is a great need for a better alternative. Together with Aeras, we are developing the novel TB vaccine candidate AERAS-402/Crucell Ad35. The vaccine is based on Crucell s innovative AdVac technology, which uses novel harmless adenoviruses as vaccine vectors (vehicles). We are using the adenovirus 35 (Ad35) vector for this particular vaccine. AERAS-402/Crucell Ad35 is being designed as a booster vaccine that will be given to people who have previously been vaccinated with the traditional TB vaccine or an improved, recombinant version of the BCG vaccine that is being developed by Aeras. The BCG vaccine will prime (prepare) the immune system to fight off TB infection and the AERAS-402/ Crucell Ad35 will be given later to boost this initial immune response. Data from AERAS-402/Crucell Ad35 clinical trials (Phase I and II) support the immunogenicity and acceptable safety profile of the candidate TB vaccine. In 2009, an estimated 1.7 million people died of tuberculosis. Source: WHO, Global TB Control 2010 report. Tuberculosis Estimated new TB cases (all forms) per 100,000 population in >300 No estimate
17 Our business Research and development 15 Malaria Countries or areas at risk of transmission in Transmission occurs Limited risk of transmission No report Source: WHO, World Malaria Report Malaria (Phase I) Malaria is one of the most prevalent infections in tropical and subtropical regions. Children and pregnant women are most severely affected. According to the World Health Organization (WHO), half of the world s population is at risk of malaria, and an estimated 225 million cases led to 781,000 deaths in There is currently no licensed vaccine to protect people against malaria, a disease caused by infection with the Plasmodium parasite and transmitted by mosquitoes. Therapies are available for malaria patients, but the worsening problem of drug resistance in many parts of the world is making adequate treatment and control of malaria increasingly difficult. In addition, many insecticides are no longer useful against the mosquitoes that transmit the disease. Crucell is working in collaboration with a number of research groups to develop a safe, effective and affordable vaccine against Plasmodium falciparum, the most lethal of the four species of malaria parasite that infect humans. Crucell s approach is based on our innovative AdVac technology, which uses novel, harmless adenoviruses as vaccine delivery vehicles (vectors). In April, 2010, Crucell entered into an agreement with GlaxoSmithKline Biologicals (GSK) to collaborate on developing a second-generation malaria vaccine candidate. Crucell is contributing the recombinant malaria vaccine candidate Ad35-CS, based on Crucell s PER.C6 and AdVac technologies, while GSK is contributing its late-stage malaria vaccine candidate RTS,S/AS. The collaborative partners aim to advance this new vaccine candidate into human clinical studies with the support of the PATH Malaria Vaccine Initiative (MVI). Clinical efficacy challenge trials sponsored by the MVI will be initiated in 2011 at the US Walter Reed Army Institute of Research, providing all agreements are finalized. Pending the results of these Phase I/IIa trials, Crucell and GSK expect to advance the prime boost candidate in further clinical studies with the support of public or non-profit partners who are interested in accelerating the development of a malaria vaccine. In May 2010, Crucell announced the start of a new Phase I clinical study in Burkina Faso, West Africa. Crucell is developing its malaria vaccine vector, Ad35-CS, in collaboration with National Institute of Allergy and Infectious Diseases (NIAID)/ National Institutes of Health (NIH), the Centre National de Recherche et de Formation sur le Paludisme (CNRFP) in Burkina Faso, and the Noguchi Memorial Institute for Medical Research at the University of Ghana. Enrolment has been completed and boost vaccinations are ongoing. This is the first study evaluating the safety and immunogenicity of this AdVac -based malaria vaccine vector candidate in a population living in a malaria endemic area. Ebola and Marburg (Phase I) Ebola and Marburg are among the world s most lethal viral diseases. Both Ebola and Marburg are among the few viruses causing hemorrhagic fever, a severe, often fatal disease in humans. There are currently no vaccines or antiviral therapies available for either disease. Crucell is developing a multivalent filovirus vaccine against Ebola and Marburg in collaboration with the Vaccine Research Center of the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The candidate vaccine is based on Crucell s proprietary adenoviral vector technology and is produced using Crucell s PER.C6 technology.
18 16 Our business Research and development In August 2010, Crucell announced its participation in an international Phase I clinical trial in the United States and Africa of a combination of two AdVac -based AIDS vaccine candidates, Ad26.ENVA.01 and Ad35-ENV, in healthy adults who are not infected with HIV. The clinical trial, which will be led by the International AIDS Vaccine Initiative (IAVI), represents a collaboration between IAVI, Crucell, the Ragon Institute, and Beth Israel Deaconess Medical Center (BIDMC), a major teaching hospital of Harvard Medical School. In 2008, an estimated 2.7 million people were newly infected with HIV. Source: WHO. Every 17,5 seconds one person dies of AIDS. Source: Stop Aids Now! HIV (Phase I) Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in which the immune system progressively fails, leading to life-threatening infections. Over the past 25 years, HIV infection resulting in AIDS has claimed millions of lives, devastated communities, and enormously frustrated efforts to fight poverty, improve global health and promote economic development. According to the 2010 Progress Report (a joint report by UNAIDS, Unicef and WHO), the HIV epidemic remains a major global public health challenge, with a total of 33.4 million people living with HIV worldwide. In 2008 alone, 2.7 million people were newly infected with HIV. The Ad26.ENVA.01 vaccine candidate used in this study is developed and manufactured by Crucell, while the Ad35-ENV vaccine is developed by IAVI. Both vaccines candidates are based on Crucell s proprietary AdVac technology. The planned Phase 1 trial of the vaccine combination represents a key step towards proof of concept studies to evaluate the efficacy of the vaccine combination in humans. HPV (Discovery/Pre-clinical) Genital infection with human papilloma virus (HPV) is very common in both men and women and usually spontaneously clears within one year after infection. In about 1% of individuals, however, HPV persists and ultimately results in genital neoplastic lesions. 1 Source: WHO, factsheet on rabies.
19 Our business Research and development 17 In November 2010, Crucell announced the start of a discovery program leading to the development and commercialization of a therapeutic HPV vaccine. The discovery program is part of a strategic collaboration, signed in September 2009 with Johnson & Johnson, through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals, Inc., to develop innovative products, including antibodies for influenza prevention and treatment. RSV (Discovery/Pre-clinical) Respiratory syncytial virus (RSV) is the most important cause of viral lower respiratory tract illness in infants and children. RSV-induced disease is the last of the major paediatric diseases for which no preventive vaccine is available. Current prevention in developed countries is based on the administration of a costly RSV-neutralizing antibody, which is given to high-risk infants, in particular premature newborns. RSV also induces severe disease in immunocompromized adults and elderly people with weak immune systems, for whom the RSV antibody is not available. In June 2010, Crucell announced the start of a discovery program leading to the development and commercialization of a universal RSV vaccine. The vaccine will be designed to prevent severe infections with the most common RSV strains in infants and the elderly. This discovery program is part of a strategic collaboration with Johnson & Johnson, signed in September As an encouragement towards the RSV research community, Crucell sponsored the VII Respiratory Syncytial Virus Symposium held in December 2010 and established the Innovation Award for RSV Research. This support highlights Crucell s long-standing commitment to improve the health of people worldwide by advancing the fight against infectious diseases. Antibody development Antibodies are proteins made naturally by cells of the body s immune system. They function as one of the body s principal defense mechanisms against pathogens disease-causing agents such as parasites, viruses or bacteria. As antibodies recognize and bind to invading pathogens, ultimately eliminating them, they play a crucial role in protecting humans against disease. Rabies antibody combination (Phase II) Rabies is a viral disease of mammals and is most often transmitted through the bite of a rabid animal. The virus infects the central nervous system, causing encephalitis (inflammation of the brain) and ultimately death if appropriate medical intervention is not given promptly. Every year, more than 15 million people worldwide receive a post-exposure preventive regimen to avert the disease. This is estimated to prevent 327,000 rabies deaths annually. 1 Nevertheless, an estimated 55,000 individuals exposed to rabies virus mostly children die each year. Most of those who die receive a rabies vaccine only, rather than the proper post-exposure treatment consisting of anti-rabies antibodies as well as a vaccine. Concerns about the availability and safety of the current, blood-derived antibody treatment have prompted the search for a safe, effective and affordable alternative.
20 18 Our business Research and development Since January 2008, the route toward global availability of this next-generation, life-saving rabies biological has been facilitated by a strategic partnership between Crucell and sanofi pasteur, a world leader in rabies immunization. Under the terms of this agreement, Crucell will be responsible for manufacturing the commercial product and has retained exclusive distribution rights in Europe, co-exclusive distribution rights in China and the rights to sell to supranational organizations, while sanofi pasteur will have exclusive distribution rights for all other territories and co-exclusive distribution rights in China. A planned Phase II trial in India is expected to start in the first half of This study is designed to collect data on the safety and neutralizing activity of the rabies antibody combination plus vaccine in a simulated rabies post-exposure prophylaxis setting. An estimated 55,000 individuals exposed to rabies virus mostly children die each year. Source: WHO. Crucell scientists in collaboration with scientists from Thomas Jefferson University (TJU) in Philadelphia and the US Centers for Disease Control and Prevention in Atlanta, USA to discover a combination of human monoclonal antibodies (mabs) for the post-exposure treatment of rabies. Crucell s innovative MAbstract and PER.C6 technologies played a crucial role in the discovery and development of this promising therapy. The candidate mab product is designed to be used together with rabies vaccine. Preclinical studies conducted during 2004 indicated that the mab combination could neutralize (inactivate) rabies virus at least as effectively as blood-derived human rabies immune globulin (HRIG), the current gold standard for providing immediate protection against rabies virus. Since then, the rabies mab combination has successfully progressed through phase I clinical trials in the USA and India (in ) and phase II trials in the USA and the Philippines. The US Food and Drug Administration (FDA) has granted the rabies mab combination Fast Track status, paving the way for priority handling of the regulatory dossier. Human monoclonal antibodies against a broad range of influenza strains (Pre-clinical) Imagine a single product that could solve all the problems currently limiting influenza control. It would have to reliably protect all subgroups of the population especially the elderly against serious illness and death, regardless of the causal viral strain. Ideally, it would both prevent and cure influenza. In December 2008, Crucell announced the discovery of a new class of mabs with this extraordinary potential. Crucell also reported the results of preclinical studies involving a representative of this new mab class, CR6261. The antibody was shown to neutralize a broad range of influenza viruses, including the currently circulating H1N1 seasonal flu strains (genetic descendants of the virus responsible for 40 million deaths during the pandemic of ) and the highly pathogenic H5N1 ( bird flu ) virus. More recent tests have shown that CR6261 also combats the novel H1N1 virus that caused the 2009 pandemic. 1 Source: US National Library of Medicine, National Institute of Health.
The Onslow County Health Department Travel Clinic offers a complete line of immunizations and prescriptions to protect you while traveling abroad. The most appropriate immunizations and travel medications
Crucell 2007 Combating infectious diseases Annual Report and Form 20-F www.crucell.com Mission: Combating infectious diseases Crucell s mission is to develop, produce and market vaccines and antibodies
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
Crucell Operational Excellence: Healthy Ambition Cees de Jong Chief Operating Officer March 12 th, 2008 London Agenda Introduction COO s perspective on Crucell Marketed products Excellent scope for growth
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
WWW.BIOTECH.CA CANADA S VACCINE INDUSTRY COMMITTEE LEADERSHIP IN GLOBAL HEALTH The Vaccine Industry Committee (VIC), Canada s Voice for Vaccines The VIC is comprised of Canada s major vaccine developers
1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
Contents Babies from Birth to Age 2... 2 Vaccines give parents the power... 2 Vaccines are recommended throughout our lives... 3 Talk to your doctor... 3 Vaccines are very safe... 3 Whooping Cough (Pertussis)...
C hapter 13 WHY DO WE FALL ILL Multiple Choice Questions 1. Which one of the following is not a viral disease? (a) Dengue (b) AIDS (c) Typhoid (d) Influenza 2. Which one of the following is not a bacterial
Immunizations Recommended for Travel in Nepal Name of vaccine Dosage Booster Comment Hepatitis A - brand names (Havrix, Vaqta, Avaxim) or Twinrix (combined A&B) Hepatitis B - Engerix, Recombivax or Twinrix
Borderless Diseases By Sunny Thai Millennium Development Goal #6 6. Combat HIV/AIDS, malaria and other borderless diseases. A. Halt and begin reversing spread of HIV by 2015. B. Achieve universal access
An update on Crucell s Corporate Social Responsibility program July 2012 Passion for protection www.crucell.com 2 Passion for Protection: Crucell s Corporate Social Responsibility Program 3 Contents About
March 23, 2011 Vaccines: Poised To Deliver Significant Growth in Emerging Markets Citi Vaccine Seminar Pierre Morgon Vice President, Franchise & Global Marketing Operations Sanofi Pasteur London Forward
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
BIOLOGICAL SCIENCE CONCEPTS: BIO113 1 There are 4 portions of this review a list of objectives, a table of diseases, sample multiple choice questions, and general questions. Your notes are the most important
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):
IMMUNISATIONS You may want to know if your child should have routine immunisations and whether there could be an increased risk of complications because of the heart condition. We have sought the opinions
Seven Key Reasons Why immunization must remain a priority in the WHO European Region A dramatic decrease in cases of vaccine-preventable diseases has made many infectious diseases seen as a thing of the
It takes a planet: global implications/consequences of local vaccine refusal Meg Fisher, MD Medical Director Disclosures I have no disclosures. I may be mentioning off label uses of vaccines. Objectives/Outcomes
VACCINE Table 1. Spanish Association of Paediatrics Immunisation Schedule. Recommendations of the Advisory Committee on Vaccines Age in months Age in years 0 2 4 6 12-15 15-18 2-3 4-6 11-12 Hepatitis B
EMA/14365/2014 Summary of the risk management plan (RMP) for Tritanrix HB [Diphtheria, tetanus, pertussis (whole cell) and hepatitis B (rdna) vaccine (adsorbed)] Overview of disease epidemiology Diphtheria
Novel Influenza H1N1 Joseph C. Frantz, Ph.D. Director, Pharmaceutical Technology Sanofi Pasteur, Swiftwater, PA Lecture Outline Origins of a virus Microbiology of the virus Viruses and human disease Influenza
Information on Measles and Whooping Cough: Vaccination and Disease Vaccine s Mechanism of Action Vaccines expose the recipient to a small amount of an weakened organism. Through this exposure, the body
GUIDELINE Vaccination of Health Care Workers Version 2 December 2012 Centre for Healthcare Related Infection Surveillance and Prevention Introduction This guideline provides information to support Hospital
Vaccination: It s what your child would choose No-one likes an injection, but your child would never choose to suffer from serious conditions like measles, mumps or whooping cough. Your guide to childhood
1 Immunization Information for Blinn College Students *Important Information Regarding the Bacterial Meningitis Vaccine* The State passed Senate Bill 1107 in 2011 and recently Senate Bill 62 in 2013, which
FREQUENTLY ASKED QUESTIONS ON PENTAVALENT 1 Frequently asked questions on Pentavalent Two additional vaccines have been added to the DPT vaccine, namely total of 5 vaccines in one injection which is called
Ambulance Service Patient Care and Transportation Standards Patient Care A. General Each operator and each emergency medical attendant and paramedic employed by the operator, shall: (a) Ensure that each
Immune System and Disease Homeostasis Q: How does the body fight against invading organisms that may disrupt homeostasis? WHAT I KNOW WHAT I LEARNED 35.1 How do people catch infectious diseases? SAMPLE
Travel Vaccinations Travel vaccinations are an essential part of holiday and travel planning, particularly if your journey takes you to an exotic destination or 'off the beaten track'. The risks are not
Grippeimpfung (Englisch) Schwangere Information for expectant mothers Flu Vaccination Vaccination during pregnancy protects both mother and unborn child. Staying healthy during pregnancy During pregnancy,
Valneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013 Revenue Ahead of Guidance and Cash Target Met in First year Following Merger Total revenues and grants
Name: Date: Period: Making Background: A vaccine against a disease works by generating an immune response in the body against some kind of pathogen a virus, bacterium or some other agent that causes the
General Information 2009 Novel H1N1 Influenza Vaccine Key Points Messages: Please be patient. Vaccine will be coming. Meanwhile, use other prevention methods such as hand washing, covering coughs and sneezes,
Vaccines Active vs Passive Immunization Active is longer acting and makes memory and effector cells Passive is shorter acting, no memory and no effector cells Both can be obtained through natural processes:
William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016 Advisory Committee on Immunization Practices (ACIP) The recommendations to be discussed are primarily those of the ACIP composed of 15
Disease, travel and vaccinations You are planning to travel on vacation or business does your destination require a vaccination? If you are planning to stay in a resort or a city and you are in good health,
Immunology Ambassador Guide (updated 2014) Immunity and Disease We will talk today about the immune system and how it protects us from disease. Also, we ll learn some unique ways that our immune system
Pentavalent Vaccine Guide for Health Workers with Answers to Frequently Asked Questions Ministry of Health and Family Welfare Government of India 2012 Immunization is one of the most well-known and effective
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
Frequently Asked Questions (FAQs) Research Rationale 1. What does PrEP stand for? There is scientific evidence that antiretroviral (anti-hiv) medications may be able to play an important role in reducing
Transient Hypogammaglobulinemia of Infancy Chapter 7 An unborn baby makes no IgG (antibody) and only slowly starts producing it after birth. However, starting at about the sixth month of pregnancy, the
Factsheet September 2012 Pertussis immunisation for pregnant women Introduction The routine childhood immunisation programme has been very effective in reducing the overall numbers of cases of pertussis.
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
Health Information in Tomorrow s World The Health Academy e-learning COURSES Courses Developed 1 1. All the Way to the Blood Bank Around the world, AIDS is shattering young people's opportunities for healthy
Current Trends in Immunization Christian Lease Director, Immunization Policy, Novartis Vaccines 2011 NCSL Meeting Objectives Review the benefits of immunization Discuss where the immunization enterprise
NIT do INSTITUTO BUTANTAN 1901 Established to produce serum against the bubonic plague Vital Brazil, first director, investigated antivenoms against snake bites 800.000 m 2 INSTITUTO BUTANTAN 23 scientific
Karmell J. Macoretta, MSN, ANP-BC Presented at the 7 th Annual Meeting of the WNY Pediatric, Adolescent and Adult Immunization Coalitions What is a routine vaccine? What is a travel vaccine? Routine Travel
What is whooping cough Ocument dn (pertussis)? Information and Prevention IMPORTANT Pertussis (or whooping cough) is a highly contagious infection that can cause uncontrollable, violent coughing. If you
HIV & AIDS What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease. What does HIV stand for? Human Immunodeficiency Virus Where did HIV
The Basics Why should I get vaccinated? Vaccination is the best way to protect against infections that can make you sick and be passed on to those around you. 1 What kinds of side effects will I get from
FOR IMMEDIATE RELEASE Release #2014-04 CONTACT for this Release: Krista Dommer Office Phone: (209) 468-3571 Email: firstname.lastname@example.org Alvaro Garza, MD, MPH. Public Health Officer MEASLES OUTBREAKS PROMPT
Pregnant? There are many ways to help protect you and your baby Immunise against: Flu (Influenza) Whooping cough (Pertussis) German measles (Rubella) mmunisation This leaflet describes the vaccinations
Influenza Vaccine Frequently Asked Questions Influenza Control Program Influenza or the flu can be a serious contagious disease, which is spread by droplet transmission through close contact with an infected
Immunization Healthcare Branch Meningococcal Vaccination Program Questions and Answers Prepared by Immunization Healthcare Branch (IHB), Defense Health Agency Last Updated: 27 Mar 06 www.vaccines.mil 877-GET-VACC
Information letter from the Norwegian Institute of Public Health No. 3 National childhood vaccination programme in Norway English Last updated July 2010 www.fhi.no/publ/infoletter Vaccination of children
Public Health Activities & Services Inventory Technical Notes COMMUNICABLE DISEASE CLINICAL SERVICES, SURVEILLANCE AND CONTROL In 2014, decision was made to adopt number of national public health activities
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) email@example.com The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?
New York State Department of Health Immunization Program Combined Hepatitis A and B Vaccine Dosing Schedule Policy Policy Statement The accelerated four-dose schedule for combined hepatitis A and B vaccine
DON T GET OR GIVE THE FLU THIS YEAR THANK YOU Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2013-2014 Healthcare workers prevent the spread of flu and
GENERAL INFORMATION What is hepatitis B? Hepatitis B is the world's most common liver infection that can lead to cirrhosis and liver cancer. It is caused by the hepatitis B virus (HBV), which attacks and
Prevention & Control of Viral Hepatitis Infection: A Strategy for Global Action World Health Organization 2011. All rights reserved. The designations employed and the presentation of the material in this
FDA Update on the H1N1 Flu Vaccine and Antiviral Medications Beth Fabian Fritsch, R.Ph., M.B.A. Commander, U.S. Public Health Service Health Programs Coordinator Office of Special Health Issues Food and
FRED UPTON, MICHIGAN CHAIRMAN ONE HUNDRED FOURTEENTH CONGRESS Congress of the United States House of Representatives COMMITTEE ON ENERGY AND COMMERCE 2125 RAYBURN HOUSE OFFICE BUILDING WASHINGTON, DC 20515-6115
ACCESS TO THE SEASONAL FLU VACCINE IN CANADA How the flu shot makes its way from the laboratory to the doctor s office. Health Canada is the federal department responsible for helping Canadians maintain
Preventing Cervical Cancer with Gardasil Jana Ogden RN, MSN, MBA-HCA, IHCC Nursing Faculty Upon Completion of the Lesson the student will be able to: Review statistics related to cervical cancer and HPV
News Release FOR IMMEDIATE RELEASE Merck Contact: Mary Elizabeth Blake (215) 652-5558 Merck Investor Contact: Graeme Bell (908) 423-5185 HVTN Contact: Sarah Alexander (206) 910-3801 Vaccination and Enrollment
VACCINE SAFETY Suzette H. Lazo, MD Asian Pacific Vaccinology Meeting Bangkok, Thailand Nov.30-Dec.3, 2015 Weighing Vaccine s Benefits versus Risks (38.3 C) Centers for Disease Control and Prevention. Possible
INTELLECTUAL PROPERTY ISSUES IN VACCINE DEVELOPMENT Cecilia Oh Global Health and Technology Access Program Duke University Outline Changes in global vaccines market IPRs and vaccine development Lessons
BIOTRON LIMITED (ASX:BIT) Mid-Clinical Stage Antiviral Drug Development Company Investor Update 20 August 2015 Dr Michelle Miller Managing Director +61 412 313329 firstname.lastname@example.org www.biotron.com.au
Institute for OneWorld Health a nonprofit pharmaceutical company Oxymoron no more: nonprofits can deliver medicines for the poor of the world January 10, 2005 Victoria Hale, PhD CEO, OneWorld Health The
PRIORITY RESEARCH TOPICS Understanding all the issues associated with antimicrobial resistance is probably impossible, but it is clear that there are a number of key issues about which we need more information.
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,
Policy Number IMM10012009SC Approved By Vaccination (Immunization) UnitedHealthcare Medicare Committee Current Approval Date 04/08/2015 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable
FACT SHEET LEADING DENGUE VACCINE CANDIDATE COULD CHANGE THE LIVES OF MILLIONS A GLOBAL PUBLIC HEALTH CHALLENGE Dengue fever, a mosquito-borne disease caused by four types of dengue viruses, is a threat
Government of the Republic of Trinidad and Tobago MINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS Influenza vaccines are one of the most effective ways to protect
Single celled organisms Single Celled Organisms Some organisms, unlike plants and animals, consist of only one cell. These organisms are said to be unicellular An amoeba is another name given to an organism
Guidelines for Vaccinating Pregnant Women U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Disease Control & Prevention Guidelines for Vaccinating Pregnant Women from Recommendations of the Advisory
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
Brochure More information from http://www.researchandmarkets.com/reports/836340/ World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments Description: World Vaccines Market 2008-2013:
INFORMATION DRIVES SOUND ANALYSIS, INSIGHT PHARMACY BENEFIT ADVISORY Introduction According to the Centers for Disease Control and Prevention (CDC), the rate of new hepatitis C virus (HCV) infections in
Your consent to our cookies if you continue to use this website.